, the authors recently showed that mice lacking either TLR2, TLR4 or the key TLR signalling molecule MyD88 (myeloid differentiation primaryresponse gene 88) fail to remit from central nervous system (CNS) inflamma tory attack in experimental autoimmune encephalomyelitis (EAE) owing to deficient IL10 production by B cells 3 . On the basis of this work, they propose the interesting teleo logical explanation that exposure to certain microbial infections evolved a TLRmediated mechanism wherein Bcell IL10 protects from the development of chronic inflammatory diseases, such as multiple sclerosis.
The authors' work 3 , however, primarily highlights the role of memory Bcell IL10 in downregulating the active inflammatory response in EAE (that is, disease remission), less so the role of Bcell IL10 in the preven tion of chronic inflammatory disease. Is it the authors' opinion that we largely rely on infec tious agents to generate the regulatory B cells that contribute not only to recovery from exac erbation of autoimmune disease, but also to the maintenance of immune homeostasis and thus our ability to avoid the initial development of autoimmune disease?
As an alternative teleological explanation for these findings 3 , we suggest that TLRinduced immune downregulation by memory Bcell IL10 evolved as a mechanism that limits oth erwise adaptive pathogenspecific responses (T H 1cell and/or T H 17cell responses) from becoming overly aggressive. This would be expected to occur when memory B cells integrate sufficiently strong stimulatory sig nals, such as combined engagement of TLR, Bcell receptor (BCR) and CD40, during vigorous adaptive immune responses, such as pathogenspecific responses. IL10 induced in these B cells could then contribute through a 'negativefeedback loop' to downregulate the local immune response, thereby limiting excessive selftissue damage. The existence of such a mechanism as part of the normal resolution of pathogenspecific responses could also contribute to the remission from a dysregulated adaptive immune response, such as exacerbation of a T H 1 or T H 17celldriven autoimmune disease 4 . We further propose that Bcell IL10 has evolved for more than one regulatory pur pose relevant to autoimmune disease, and that the expression of regulatory IL10 from B cells depends on both the context of activa tion and the Bcell subset involved. Although IL10 induced from B cells by TLR signalling may be most relevant to the remission phase of autoimmune disease, there are examples of Bcell IL10 contributing to protection from the development of both induced and spontaneous autoimmune diseases 5, 6 . Fillatreau et al. nicely highlight the context wherein mouse memory B cells produce IL10 when activated by the combination of TLR stimulation and BCR and CD40 engagement. They comment that combined BCR and CD40 stimulation is insuf ficient to elicit IL10 production from naive B cells and suggest that naive B cells require TLR signals to produce IL10. In contrast to these observations in mice, however, recent human data indicate that isolated CD40 stimulation (in the absence of either TLR signalling or BCR engagement) induces significant IL10 production from naive B cells 7, 8 . One potential explanation is that in humans, who live in a 'dirtier' environment than laboratory housed animals, the naive B cells are primed in vivo with TLR signalling, and can then more read ily be induced to make IL10 on partial signal ling 3, 9 . Although such an explanation would be in keeping with the authors' reference to the hygiene hypothesis, it seems insufficient, as human memory B cells from the same individuals do not produce IL10 under either isolated CD40 stimulation or combined BCR and CD40 engagement 7, 8 . Our preferred explanation is that both naive and memory B cells have evolved the capacity to produce immune regulatory IL10, and that such production depends on the signals they receive in a particular activation context (see figure) . We propose that memory Bcell IL10 B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators production evolved primarily to downregulate vigorous adaptive pathogenspecific immune responses (involving combined TLR, BCR and CD40 signalling) and would also contribute to the resolution of autoimmune disease exacer bation (see part a of figure) . By contrast, naive B cells produce IL10 when stimulated in a 'bystander' activation context through non cognate interaction with an activated T cell (CD40 signalling only, independent of either TLR or BCR signalling). This IL10 produc tion by naive B cells (that normally harbor the autoreactive Bcell repertoire) is probably most relevant to early Bcell-Tcell interac tions and the maintenance of normal immune homeostasis (see part b of figure) . So, in the context of autoimmune disease regulation, naive Bcell IL10 production may function primarily in the prevention of inflammatory responses in autoimmune disease, whereas memory Bcell IL10 production may func tion primarily as a mechanism of resolving active disease exacerbation.
Evidence is mounting that Bcell IL10 can regulate immune responses in both health and disease. As Fillatreau et al. note in their Opinion paper, TLRmediated IL10 induc tion represents one such context. It is likely that Bcellderived regulatory IL10 has evolved to serve distinct immune functions, and that these functions are in turn care fully regulated in a cellsubset and context dependent manner.
